Prevention and early diagnosis of ototoxic hearing loss
2020 CODEPEH recommendations
Abstract
Núñez, F. (2021). Prevención y diagnóstico precoz de la sordera por ototóxicos: recomendaciones CODEPEH 2020. Revista Española de Discapacidad, 9(2), pp. 155-178.
References
Abujamra, A. L. et al. (2013). The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy. Pediatr Blood Cancer, 60, pp. 474-478.
Arslan, E. et al. (1999). Global problem of drug-induced hearing loss. Ann N Y Acad Sci, 884, pp. 1-14.
Astolfi, L. et al. (2016). Coenzyme Q10 plus multivitamin treatment prevents cisplatin ototoxicity in rats. PLoS One, 11(9), p. e0162106.
Bass, J. K. y Bhagat, S. P. (2014). Challenges in ototoxicity monitoring in the pediatric oncology population. J Am Acad Audiol, 25, pp. 760-774.
Bisht, M. y Bist, S. S. (2011). Ototoxicity: the hidden menace. Indian J Otolaryngol Head Neck Surg, 63, pp. 255-259.
Bitner-Glindzicz, M. et al. (2009). Prevalence of mitochondrial 1555A-->G mutation in European children. N Engl J Med, 360(6), pp. 640-642.
Brock, P. R. et al. (2012). Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol, 30, pp. 2408-2417.
Budai, B. et al. (2020). Géczi GSTM1 null and GSTT1 null: Predictors of cisplatin-caused acute ototoxicity measured by DPOAEs. J Mol Med (Berl), 98(7), pp. 963-971.
Cianfrone, G. et al. (2011). Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: A reasoned and updated guide. Eur Rev Med Pharmacol Sci, 15(6), pp. 601-636.
Clemens, E. et al. (2019). Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol, 20, pp. E29-E41.
Clemens, E. et al. (2020). Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCare LIFE Study. Pharmacogenomics J, 20(2), pp. 294-305.
Coradini, P. P. et al. (2007). Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol, 29, pp. 355-360.
Crabb, S. J. et al. (2017). COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. Eur J Cancer, 87, pp. 75-83.
Crundwell, G. et al. (2016). Ototoxicity (cochleotoxicity) classifications: A review. Int J Audiol, 55(2), pp. 65-74. Davis, B. D. (1987). Mechanism of bactericidal action of aminoglycosides. Microbiol Rev, 51, pp. 341-350.
Dogan, M. et al. (2017). Protective role of misoprostol in prevention of gentamicin ototoxicity. Int J Pediatr Otorhinolaryngol, 96, pp. 140-144.
Dogan, M. et al. (2018). Utilizing prestin as a predictive marker for the early detection of outer hair cell damage. Am J Otolaryngol, 39(5), pp. 594-598.
Dos Santos, N. A. G. et al. (2020). Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents. Food Chem Toxicol, 136, p. 111079.
Drögemöller, B. I. et al. (2018). Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients. Clin Cancer Res, 24(8), pp. 1866-1871.
Dulon, D. et al. (1988). Relationship between the nephrotoxicity and ototoxicity induced by gentamicin in the Guinea pig. Acta Oto-Laryngologica, 106, pp. 219-225.
Dulon, D. et al. (2013). Ototoxicidad farmacológica. EMC-Otorrinolaringología, 42, pp. 1-13.
Duval, M. y Daniel, S-J. (2012). Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity. Journal of Otolaryngology-Head and Neck Surgery, 41(5), pp. 309-315.
El-Anwar, M. W. et al. (2018). Protective effect of pentoxifylline on amikacin-induced ototoxicity. Ear NoseThroat J, 97(8), pp. E8-E12.
El-Barbary, M. N. et al. (2015). Gentamicin extended interval regimen and ototoxicity in neonates. Int J Pediatr Otorhinolaryngol, 79, pp. 1294-1298.
Fligor, B. J. (2019). Pediatric ototoxicity: current trends and management. Seminars in Hearing, 40, pp. 154-161.
Forge, A. y Li, L. (2000). Apoptotic death of hair cells in mammalian vestibular sensory epithelia. Hear Res, 139, pp. 97-115.
Fox, D. J. et al. (2016). D-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models. Journal of Cystic Fibrosis, 15(4), pp. 518-530.
Fransson, A. E. et al. (2017). Hydrogen inhalation protects against ototoxicity induced by intravenous cisplatin in the Guinea pig. Front Cell Neurosci, 11, p. 280.
Freyer, D. R. et al. (2017). Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): A multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncology, 18(1), pp. 63-74.
Ganesan, P. et al. (2018). Ototoxicity: A challenge in diagnosis and treatment. J Audiol Otol, 22, pp. 59-68.
Gallo-Terán, J. et al. (2002). Incidence of A1555G mutations in the mitochondrial DNA and 35delG in the GJB2 gene (connexin-26) in families with late onset non-syndromic sensorineural hearing loss from Cantabria. Acta Otorrinolaringol Esp, 53(8), pp. 563-571.
Gu, J. et al. (2020). Astaxanthin-loaded polymer-lipid hybrid nanoparticles (ATX-LPN): Assessment of potential otoprotective effects. J Nanobiotechnology, 18(1), p. 53.
Guo, J. et al. (2019a). Protection of hair cells from ototoxic drug-induced hearing loss. En H. Li y R. Chai (Eds.), Hearing loss: Mechanisms, prevention and cure (pp. 17-36). Springer Nature Singapore.
Guo, S. et al. (2019b). Rapamycin protects spiral ganglion neurons from gentamicin-induced degeneration in vitro. J Assoc Res Otolaryngol, 20(5), pp. 475-487.
Hamstra, D. A. et al. (2010). Pharmacokinetic analysis and phase 1 study of MRX-1024 in patients treated with radiation therapy with or without cisplatinum for head and neck cancer. Clin Cancer Res, 16, pp. 2666-2676.
Hana, R. S. y Bawi B. L. (2018). Prestin, otolin-1 regulation, and human 8-oxoG DNA glycosylase 1 gene polymorphisms in noise-induced hearing loss. Ibnosina J Med Biomed Sci, 10, pp. 60-64.
Hirvonen, T. P. et al. (2005). Effects of intratympanic gentamicin on vestibular afferents and hair cells in the chinchilla. J Neurophysiol, 93(2), pp. 643-655.
Holzer, A. K. et al. (2004). The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol, 66, pp. 817-823.
Huang, S. et al. (2013). Proton pump inhibitor selectively suppresses proliferation and restores the chemosensitivity of gastric cancer cells by inhibiting STAT3 signaling pathway. International Immunopharmacology, 17(3), pp. 585-592.
Husain, K. et al. (2005). Partial protection by lipoic acid against carboplantin-induced ototoxicity in rats. Biomedical and Environmental Sciences, 18(3), pp. 198-206.
Igumnova, V. et al. (2019). The prevalence of mitochondrial mutations associated with aminoglycoside-induced deafness in ethnic Latvian population: The appraisal of the evidence. J Hum Genet, 64(3), pp. 199-206.
Ishikawa, M. et al. (2019). Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use. Sci Rep, 9(1), p. 2410.
Jing, W. et al. (2015). Mitochondrial mutations associated with aminoglycoside ototoxicity and hearing loss susceptibility identified by meta-analysis. J Med Genet, 52, pp. 95-103.
Juhn, S. K. et al. (1981). Nature of blood-labyrinth barrier in experimental conditions. Ann Otol Rhinol Laryngol, 90, pp. 135-141.
Kil, J. E. et al. (2017). Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 390(10098), pp. 969-979.
King, K. A. y Brewer, C. C. (2018). Clinical trials, ototoxicity grading scales, and the audiologist´s role in therapeutic decision making. Int J Audiol, 57, pp. S89-S98.
Knight, K. R. et al. (2005). Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol, 23(34), pp. 8588-8596.
Knight, K. R. et al. (2017). Group-wide, prospective study of ototoxicity assessment in children receiving cisplatin chemotherapy (ACCL05C1): A report from the Children’s Oncology Group. J Clin Oncol, 35(4), pp. 440-445.
Kotecha, B. y Richardson, G. P. (1994). Ototoxicity in vitro: Effects of neomycin, gentamicin, dihydrostreptomycin, amikacin, spectinomycin, neamine, spermine and poly-L-lysine. Hear Res, 73, pp. 173-184.
Kranzer, K. et al. (2015). A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: Implications for the treatment of multidrug-resistant TB. Thorax, 70(11), pp. 1070-1077.
Kros, C. J. y Steyger, P. S. (2019). Aminoglycoside- and cisplatin-induced ototoxicity: Mechanisms and Otoprotective Strategies. Cold Spring Harb Perspect Med, 9, p. a033548.
Kucharava, K. et al. (2019). Pasireotide protects mammalian cochlear hair cells from gentamicin ototoxicity by activating the PI3K-Akt pathway. Cell Death Dis, 10(2), p. 110.
Lanvers-Kaminsky, C. et al. (2017). Drug-induced ototoxicity: Mechanisms, pharmacogenetics and protective strategies. Clinical Pharmacology & Therapeutics, 101, pp. 491-500.
Lanvers-Kaminsky, C. y Ciarimboli, G. (2017). Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin. Pharmacogenomics, 18, pp. 1683-1695.
Laurell, G. (2019). Pharmacological intervention in the field of ototoxicity. HNO, 67(6), pp. 434-439.
Le Prell, C. G. (2019). Otoprotectants: From research to clinical application. Semin Hear, 40(2), pp. 162-176.
Lee, J. E. et al. (2004). Signaling pathway for apoptosis of vestibular hair cells of mice due to aminoglycosides. Acta Otolaryngol, 124, pp. 69-74.
Lee, S. H. et al. (2018). Circulating serum miRNA-205 as a diagnostic biomarker for ototoxicity in mice treated with aminoglycoside antibiotics. Int J Mol Sci, 19(9), p. E2836.
Lewis, M. et al. (2009). Ototoxicity in children treated for osteosarcoma. Pediatric Blood Cancer, 52, pp. 387-391.
Ma, W. et al. (2015). Ginkgolide B protects against cisplatin-induced ototoxicity: Enhancement of Akt–Nrf2–HO-1 signaling and reduction of NADPH oxidase. Cancer Chemotherapy and Pharmacology, 75, pp. 949-959.
Maru, D. y Malky, G. A. (2018). Current practice of ototoxicity management across the United Kingdom (UK). Int J Audiol, 57(sup4), pp. S76-S88.
More, S. S. et al. (2010). Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci, 30, pp. 9500-9509.
Mulry, E. y Parham, K. (2020). Inner ear proteins as potential biomarkers. Otol Neurotol, 41(2), pp. 145-152.
Nguyen, T. y Jeyakumar, A. (2019). Genetic susceptibility to aminoglycoside ototoxicity. Int J Pediatr Otorhinolaryngol, 120, pp. 15-19.
Núñez, F. et al. (2015). Recomendaciones CODEPEH 2014 (sorderas diferidas y sobrevenidas en la infancia). Revista Española de Discapacidad, 3(1), pp. 163-186.
Olivier, T. W. et al. (2019). Cognitive implications of ototoxicity in pediatric patients with embryonal brain tumors. J Clin Oncol, 37, pp. 1566-1575.
O’Reilly, M. et al. (2019). Gentamicin affects the bioenergetics of isolated mitochondria and collapses the mitochondrial membrane potential in cochlear sensory hair cells. Front Cell Neurosci, 13, p. 416.
Özel, H. E. et al. (2016). Comparison of the protective effects of intratympanic dexamethasone and methylprednisolone against cisplatin-induced ototoxicity. Journal of Laryngology & Otology, 130(3), pp. 225-234.
Paciello, F. et al. (2020). The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatininduced ototoxicity. Sci Rep, 10(1), p. 1063.
Pham, T. N. M. et al. (2020). Protective mechanisms of avocado oil extract against ototoxicity. Nutrients, 12(4), p. 947.
Prayuenyong, P. et al. (2020). The efficacy of statins as otoprotective agents: A systematic review. Clin Otolaryngol, 45(1), pp. 21-31.
Ramaswamy, B. et al. (2017). Magnetic nanoparticle mediated steroid delivery mitigates cisplatin induced hearing loss. Front Cell Neurosci, 11, p. 268.
Rizzi, M. y Hirose, K. (2007). Aminoglycoside ototoxicity. Current opinions in Otolaryngology and Head and Neck Surgery, 15(5), pp. 352-357.
Roland, P. S. y Rutka, J. A. (2004). Ototoxicity. BC Decker.
Romano, A. et al. (2020). Assessment and management of platinum-related ototoxicity in children treated for cancer. Cancers (Basel), 12(5), p. 1266.
Rybak, L. P. (1993). Ototoxicity of loop diuretics. Otolaryngol Clin North Am, 26, pp. 829-844.
Salt, A. N. y Plontke, S. K. (2005). Local inner-ear drug delivery and pharmacokinetics. Drug Discov Today, 10, pp. 1299-1306.
Sekulic-Jablanovic, M. et al. (2019). Combination of antioxidants and NFAT (nuclear factor of activated T cells) inhibitor protects auditory hair cells from ototoxic insult. J Neurochem, 22, p. e14921.
Sha, S. H. et al. (2006). Aspirin to prevent gentamicin-induced hearing loss. N Engl J Med, 354, pp. 1856-1857.
Trendowski, M. R. et al. (2019). Genetic and modifiable risk factors contributing to cisplatin-induced toxicities. Clin Cancer Res, 25(4), pp. 1147-1155.
Truong, M. T. et al. (2007). Recovery from cisplatin-induced ototoxicity: A case report and review. Int J Pediatr Otorhinolaryngol, 71, pp. 1631-1638.
van As, J. W. et al. (2019). Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database Syst Rev, 5(5), p. CD009219.
Villani, V. et al. (2016). Vitamin E neuroprotection against cisplatin ototoxicity: preliminary results from a randomized, placebo-controlled trial. Head Neck, 38(S1), p. E2118.
Vital, I. et al. (2015). Distortion-product otoacoustic emissions testing in neonates treated with an aminoglycoside in a neonatal intensive care unit. Ear Nose Throat J, 94, pp. 156-165.
Waissbluth, S. (2020). Clinical trials evaluating transtympanic otoprotectants for cisplatin-induced ototoxicity: What do we know so far? Eur Arch Otorhinolaryngol, 277(9), pp. 2413-2422.
Watanabe, K. et al. (2003). Expression of caspase-activated deoxyribonuclease (CAD) and caspase 3 (CPP32) in the cochlea of cisplatin (CDDP)-treated Guinea pigs. Auris Nasus Larynx, 30, pp. 219-225.
Weiss, A. et al. (2018). Audiological monitoring in Swiss childhood cancer patients. Pediatr Blood Cancer, 65, p. e26877.
Yao, L. et al. (2020). Mechanisms and pharmacokinetic/pharmacodynamic profiles underlying the low nephrotoxicity and ototoxicity of etimicin. Acta Pharmacol Sin, 41(6), pp. 866-878.
Yorgason, J. G. et al. (2006). Understanding drug ototoxicity: Molecular insights for prevention and clinical management. Expert Opinion on Drug Safety, 5, pp. 383-399.
Yu, X. et al. (2018). Paeoniflorin reduces neomycin-induced ototoxicity in hair cells by suppression of reactive oxygen species generation and extracellularly regulated kinase signalization. Toxicol Lett, 285, pp. 9-19.
Zada, S. L. et al. (2020). Chemical modifications reduce auditory cell damage induced by aminoglycoside antibiotics. J Am Chem Soc, 12(6), pp. 3077-3087.
As an open access journal, access to the contents of the journal will be free of charge and the property rights are subject to a Creative Commons license. More specifically, the magazine will be licensed under the 'Attribution - Non-Commercial - No Derivative Works (by-nc-nd') license. This license allows free use of the content, but does not allow commercial use of the original work or the generation of derivative works.
